v3.22.2.2
Note 3 - Merger with Old Cytocom (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
  

July 27, 2021

 

Number of shares of the combined company owned by Cleveland BioLabs, Inc. stockholders

  15,478,945(1)

Multiplied by the price per share of Cleveland BioLabs, Inc. common stock

 $4.99(2)

Total purchase price

 $77,239,936 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
  

July 27, 2021

 

Tangible Assets Acquired

    

Cash and cash equivalents

 $13,116,460 

Other receivables

  25,142 

Other current assets

  44,507 

Fixed assets - net

  4,954 

Panacela (67.57% ownership)

  178,388 

Total Tangible Assets

  13,369,451 
     

Assumed Liabilities

    

Accounts payable

  (426,570

)

Accrued expenses

  (41,755

)

Total Liabilities

  (468,325

)

Net Tangible Assets/Liabilities

  12,901,126 

Intangible Assets Acquired

    

Goodwill

  64,338,810 

Total Net Assets Acquired

 $77,239,936 
Business Acquisition, Pro Forma Information [Table Text Block]
  

Nine Months Ended September 30,

 
  

2021

  

2022

 

Revenue

 $1,665,992  $2,437,139 

Net loss

 $(24,612,658

)

 $(14,607,395)